Scientific publications - Median Technologies

Antoine Iannessi [1], Hubert Beaumont [2], Christophe Hebert [3], Claire Dittlot [4], Marie Noëlle Falewee [5] - Affiliations: [1] Department of Radiology, Centre Antoine Lacassagne, Nice, France. [2] Median Technologies, Valbonne, France. [3] Department of Oncology, Centre Antoine Lacassagne, Nice, France. [4] Department of Gerontology, Centre Hospitalier Universitaire, Nice, France. [5] Department of Nutrition, Centre Antoine Lacassagne, Nice, France.

The measure of body surface area (BSA) is a standard for planning optimal dosing in oncology. This index is derived from a model having questionable performances. In this study, we proposed measurement of BSA from whole body CT images (iBSA). We tested the reliability of iBSA assessments and simulated the impact of our approach on patient chemotherapy dosage planning. Published: February 14, 2018

Nakano Y [1], Oubel E [1], Brag J [1], Doreille A [2], Lucidarme O [2]. Affiliations: [1] Median Technologies, Valbonne, France. [2] Hopital La Pitie Salpetriere, Paris, France.

NASH is a growing contributor to chronic liver disease and already represents the second highest cause of hepatocellular carcinoma in the United States. Current diagnosis and severity assessment typically relies on histopathological analysis from biopsy samples. With novel NASH therapies under development there is a need for reliable non-invasive assessment of disease progression. The aim of the study is to demonstrate the feasibility of using routine CT imaging protocols, combined with big data processing for extracting radiological signatures, for assessing disease progression in NASH patients. Poster presentation at: The NASH Biomarker Workshop 2017, May 5-6, 2017, Washington DC, USA